Neoepitope detection of disease using protein arrays
US-2015355183-A9 · Dec 10, 2015 · US
Anti-Ly6E antibodies and methods of use
US9290578B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9290578-B2 |
| Application number | US-201414518294-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 20, 2014 |
| Priority date | Oct 21, 2013 |
| Publication date | Mar 22, 2016 |
| Grant date | Mar 22, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated antibody that binds to Ly6E, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:32, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:34, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:29; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:30; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:31. 2. The antibody of claim 1 , comprising (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:28; (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:27; or (c) a VH sequence as in (a) and a VL sequence as in (b). 3. The antibody of claim 2 , comprising (a) a VH sequence of SEQ ID NO:28; (b) a VL sequence of SEQ ID NO: 27; or (c) a VH sequence of SEQ ID NO:28 and a VL sequence of SEQ ID NO:27. 4. The antibody of claim 1 , which is a monoclonal antibody. 5. The antibody of claim 4 , which is a mouse, rabbit, human, humanized, or chimeric antibody. 6. The antibody of claim 4 , which is an IgG selected from IgG1, IgG2a, IgG2b, IgG3, and IgG4. 7. The antibody of claim 1 which is conjugated to a label. 8. The antibody of claim 7 , wherein the label is a positron emitter. 9. The antibody of claim 8 , wherein the positron emitter is 89 Zr. 10. An immunoconjugate comprising the antibody of claim 1 and a cytotoxic agent. 11. A pharmaceutical formulation comprising the immunoconjugate of claim 10 and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
- G01N33/57545Primary
of the ovaries · CPC title
of the large intestine, e.g. colon, rectum or anus · CPC title
of the liver or pancreas · CPC title
of the breast · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9290578B2 cover?
- The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.
- Who is the assignee on this patent?
- Genentech Inc
- What technology area does this patent fall under?
- Primary CPC classification G01N33/57545. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Mar 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).